Sign in

You're signed outSign in or to get full access.

Mike

Research Analyst at Northland Securities

Mike Grondahl is Head of Equities/Director of Research and Senior Research Analyst at Northland Securities, specializing in financial technology, business services, and growth sectors including fintech and crypto-related companies. He covers specific companies such as Applied Digital (APLD), Green Dot (GDOT), Euronet Worldwide (EEFT), Bitdeer Technologies (BTDR), Sezzle (SEZL), and Bitfarms (BITF), with a strong performance track record including a 47% success rate, average return per rating of +18.10% over one year, and top rankings like #8 in TipRanks’ 2020 Top 100 Wall Street Analysts and #10 in 2024 Top 10 US Stock Analysts. Grondahl joined Northland Capital Markets in January 2016 as Head of Equity Research, advanced to Head of Institutional Equity Sales, Trading and Research in 2017, and took his current role in 2025, bringing over 25 years of institutional research experience from prominent investment banks and buy-side firms, plus prior public accounting at Ernst & Young and Deloitte & Touche. He holds FINRA SIE, Series 7, Series 24, Series 63, and Series 86/87 registrations, and graduated summa cum laude from the University of St. Thomas.

Mike's questions to Intellia Therapeutics (NTLA) leadership

Question · Q4 2025

Mike asked about the gating factors to get the ATTR studies back up and running, and what has been heard from regulators regarding the path forward for ATTR-CM.

Answer

President and CEO John Leonard explained that gating factors for PN are local operational issues at sites (IRB submissions, local regulatory considerations), with active accrual expected soon and full accrual by year-end. For CM, the gating factor is receiving an FDA letter lifting the hold. He reiterated active engagement with the FDA and significant progress, but the hold is not lifted until the letter is received.

Ask follow-up questions

Fintool

Fintool can predict Intellia Therapeutics logo NTLA's earnings beat/miss a week before the call

Question · Q4 2025

Mike inquired about the gating factors for getting the ATTR studies back up and running, and what Intellia has heard from regulators regarding the path forward for ATTR-CM.

Answer

President and CEO John Leonard explained that for the PN study, gating factors are local, operational issues at sites, with active accrual expected soon and full accrual by year-end. For the CM study, the gating factor is receiving an FDA letter lifting the hold. He stated that Intellia has been very actively engaged with the FDA and is very far along in addressing questions, and will provide updates as soon as a decision is received, followed by similar local operational processes.

Ask follow-up questions

Fintool

Fintool can write a report on Intellia Therapeutics logo NTLA's next earnings in your company's style and formatting

Mike's questions to MITEK SYSTEMS (MITK) leadership

Question · Q1 2026

Mike from Northland Securities asked about the expansion of Mitek's sales force headcount and marketing budget, and sought more details on the progress and conversion timelines of larger Check Fraud Defender pilot programs.

Answer

CEO Ed West confirmed expanded headcount, including hunters, channel partners, and SDRs, while CFO Dave Lyle noted ongoing investments in R&D and go-to-market throughout 2026, emphasizing efficiency gains from a unified sales force. Regarding Check Fraud Defender, Ed West highlighted billions of annual transactions through pilots, deepening customer engagement, and the increasing value of the data asset, but stated there's no fixed average life for pilots, with updates provided as progress continues.

Ask follow-up questions

Fintool

Fintool can predict MITEK SYSTEMS logo MITK's earnings beat/miss a week before the call